Sellas Life Sciences: Why a Response Rate Is Not the Same as a Survival Signal
Published on 11/16/2026 at 14:31 | Editorial boerse-global.deSellas Life Sciences has stacked its near-term calendar with catalysts, but the more instructive question for investors is not how many readouts are coming — it is what each one actually measures. The company said on November 4 that it will present Phase 2 data on SLS009 at the ASH annual meeting, running December 12–15, while separately reaffirming that topline results on the primary endpoint of its Phase 3 REGAL study are still expected in November.
Those two events sit close together in time, which makes the discipline of keeping them apart more important, not less.
One drug, several distinct clinical settings
The ASH presentation covers a Phase 2 study of SLS009 in combination with azacitidine and venetoclax, given to patients who had previously been treated with a venetoclax-based regimen. That treatment sequence is not a footnote — it defines the context in which the results were generated, and any assessment of the data has to account for it.
In relapsed or refractory monocytic AML, Sellas reported an overall response rate of 54% alongside a median overall survival of 5.8 months. Both figures belong to the same dataset without saying the same thing: response rate captures observed reaction to treatment, while overall survival tracks a separate clinical endpoint. Lifting the more eye-catching percentage out of that pairing flattens the finding.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
For patients with TP53-mutated AML, the company reported an overall response rate of 57% and a median overall survival of 8.8 months. The temptation to rank the two groups against each other is understandable and, on the available evidence, misplaced. These are differently defined patient populations, and preserving that distinction is more useful than folding the numbers into a single success story.
The calendar is not the result
A second SLS009 dataset is on the way: Sellas expects initial pooled data from a Phase 2 study in first-line AML in the fourth quarter of 2026. That trial has enrolled 40 patients, according to the company. It represents a different treatment setting entirely from the post-venetoclax population featured at ASH, and a shared compound name does not make the two interchangeable.
REGAL, by contrast, is a Phase 3 program. In its Thursday statement, Sellas reiterated its expectation of topline primary-endpoint data before November is out. An anticipated release, however, is not a positive study result. The date organizes expectations; only the data can answer them.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
Separating the evidence before weighing the stock
What Sellas offers, then, is a set of readouts that answer different questions rather than a single cumulative narrative. Which patient group was studied? Which endpoint was reported? And is this a delivered result or a scheduled event?
The announced ASH presentation may deepen the discussion around SLS009, but it does not substitute for the first-line data still to come, nor for REGAL's pending outcome. The right yardstick is not the volume of headlines or the number of encouraging phrases in a press release — it is whether each successive disclosure meets the clinical expectation attached to its own study. On that measure, the coming weeks and the months beyond will each have to be judged on their own terms.
Ad
Sellas Life Sciences Stock: New Analysis - 16 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
